替戈拉生与CYP2C19底物相互作用的药代动力学评估
本研究为两部分随机开放三周期交叉试验,在16名CYP2C19快代谢健康受试者中比较替戈拉生、伏诺拉生或艾司奥美拉唑对CYP2C19底物氯胍药代动力学的影响。结果显示替戈拉生对氯胍及环氯胍全身暴露无显著影响,而伏诺拉生和艾司奥美拉唑增加氯胍暴露并降低环氯胍暴露。
要点
- 替戈拉生与CYP2C19底物氯胍合用时无显著药代动力学相互作用
- 伏诺拉生和艾司奥美拉唑均增加氯胍暴露、降低环氯胍暴露
- 艾司奥美拉唑所致上述变化幅度大于伏诺拉生
核心结论
- 替戈拉生与伏诺拉生、艾司奥美拉唑不同,表现出可忽略的CYP2C19介导的药代动力学相互作用。
- 替戈拉生可作为其他抑酸药的替代选择,在临床中与CYP2C19底物合用。
研究设计与样本
- 研究为两部分、随机、开放、两序列、三周期交叉设计。
- 在16名CYP2C19快代谢健康受试者中开展,每部分8名。
主要发现
- 替戈拉生50 mg合用未显著影响氯胍和环氯胍的全身暴露。
- 伏诺拉生20 mg或艾司奥美拉唑40 mg合用增加氯胍全身暴露并降低环氯胍全身暴露。
- 艾司奥美拉唑合用所致相应变化幅度大于伏诺拉生合用。
关键数值与推荐
- 每周期单次口服阿托伐醌/氯胍250/100 mg,单用或与替戈拉生50 mg、艾司奥美拉唑40 mg(仅第1部分)或伏诺拉生20 mg(仅第2部分)合用。
- 血浆和尿液中氯胍及其代谢物环氯胍浓度测定至给药后48小时。
临床怎么用
- 临床可考虑将替戈拉生作为与其他抑酸药相比CYP2C19介导相互作用风险更低的替代选择。
- 与CYP2C19底物合用时,替戈拉生可能较伏诺拉生或艾司奥美拉唑更少引起药代动力学相互作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: CYP2C19-mediated drug interactions of acid-reducing agents are clinically important given the high possibility of concomitant administration with CYP2C19 substrates. This study aimed to evaluate the effect of tegoprazan on the pharmacokinetics (PK) of a CYP2C19 substrate, proguanil, compared with vonoprazan or esomeprazole. METHODS: A two-part, randomized, open-label, two-sequence, three-period crossover study was conducted in 16 healthy CYP2C19 extensive metabolizers (eight subjects per part). In each period, a single oral dose of atovaquone/proguanil 250/100 mg was administered alone or co-administered with tegoprazan 50 mg, esomeprazole 40 mg (Part 1 only) or vonoprazan 20 mg (Part 2 only). The plasma and urine concentrations of proguanil and its metabolite, cycloguanil, were measured up to 48 h post-dose. PK parameters were calculated using a non-compartmental method and compared between administered alone and co-administered with tegoprazan, vonoprazan or esomeprazole. RESULTS: Co-administration of tegoprazan did not significantly affect the systemic exposure of proguanil and cycloguanil. In contrast, co-administration of vonoprazan or esomeprazole increased proguanil systemic exposure and decreased cycloguanil systemic exposure, and the magnitude of the corresponding change was greater with esomeprazole co-administration than vonoprazan co-administration. CONCLUSION: Tegoprazan, unlike vonoprazan and esomeprazole, exhibited negligible CYP2C19-mediated PK interaction. It suggests that as an alternative to other acid-reducing agents, tegoprazan can be used concomitantly with CYP2C19 substrates in clinical settings. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT04568772 (Registered on September 29, 2020).
引用
- Yang E, Ji SC, Jang IJ, et al. Evaluation of CYP2C19-Mediated Pharmacokinetic Drug Interaction of Tegoprazan, Compared with Vonoprazan or Esomeprazole. Clin Pharmacokinet. 2023. PMID: 36897544. doi:10.1007/s40262-023-01228-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。